Efficacy and Safety of Erenumab in Preventive and Therapeutic Treatment of Patients Suffering from Migraine
Yatri Patel, Priyanka Patel, Viraj Panchal, Bhavya Vyas, Vishwa Parker, Devang Ashwinkumar Rana, Arya Vipul Patel, Siddharth PanchalAbstract
Background:
Erenumab, (AMG 334) is a first fully human monoclonal antibody that targets and blocks the canonical Calcitonin Gene related peptide (CGRP) receptor approved for use in migraine. CGRP plays a very pivotal role in patho-physiology og migraine. The objective were to generate statistical evidence on the basis of existing data for erenumab in terms of efficacy and safety in various treatment regimens with different dosages.
Methods:
A total of 7 RCTs following PRISMA guidelines and matching inclusion and exclusion criteria were collected of erenumab vs placebo in treatment of migraine. Studies with >50% responder rate from baseline in terms of migraine days per month at 12 week was chosen as primary clinical outcome measure. Secondary outcome chosen were mean migraine days from baseline and safety outcomes in terms of adverse events. 5.3 software was used for the calculation of Relative Risk (RR).
Results:
Data of 3615 patients were included.The use of Erenumab was associated with increased rates of achieving > 50% responder rate as compared with placebo. (RR= 1.591; 95% CI =1.322 to 1.915;
Conclusion:
Erenumab subcutaneous once monthly was the most efficacious treatment regimen and was not associated with a significant risk for treatment related adverse events.